EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Immunoassay Detection of SARS ‐ CoV ‐2 Using Monoclonal Antibody Binding to Viral Nucleocapsid Protein

Robert M Hnasko iD, Alice V Lin, Jeffery A McGarvey iD, Eric S Jackson

Microbial Biotechnology · 2025

DOI: 10.1111/1751-7915.70117 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Microbial Biotechnology, 2025. Verfasst von Robert M Hnasko und 3 weiteren Autor:innen. Beteiligte Einrichtung: United States Department of Agriculture, Agricultural Research Service, Produce Safety and Microbiology Unit, Albany, California, USA. Hauptthemen laut MEDLINE: Antibodies, Monoclonal, SARS-CoV-2, Coronavirus Nucleocapsid Proteins, COVID-19. Die Arbeit nennt 47 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: U.S. Department of Agriculture.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Immunoassays represent sensitive, easy‐to‐use, and cost‐effective tests useful for the detection of the SARS‐CoV‐2 virus. In this manuscript, we report on the binding specificity of a pair of novel monoclonal antibodies (MAbs) generated against the SARS‐CoV‐2 nucleocapsid protein (NP) and their development into sensitive sandwich enzyme‐linked immunosorbent assays (sELISA) and a lateral flow immunoassay (LFIA). Binding of these MAbs to hCoVs is limited to variants of SARS‐CoV‐2 and SARS‐CoV NP. Chemiluminescent and absorbance spectroscopy sELISAs report a limit of detection (LOD) for the SARS‐CoV‐2 B.1.1.529 NP variant at 15 pg/mL, and the LFIA using a red‐dyed 200 nm particle at 10 ng/mL. The sELISA exhibits broad SARS‐CoV‐2 viral variant detection with assay LOD for SARS‐CoV‐2 B.1.1.529 virus at 1.4 × 10 5 genome copies per mL ( p ≤ 0.001). The availability of these MAbs should facilitate continued investment in the commercial development of immunoassays to increase global SARS‐CoV‐2 detection technologies.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antibodies, MonoclonalSARS-CoV-2Coronavirus Nucleocapsid ProteinsCOVID-19Antibodies, ViralPhosphoproteinsNucleocapsid ProteinsHumansEnzyme-Linked Immunosorbent AssayImmunoassayLimit of DetectionCOVID-19 Serological Testing

Stichwörter der Autor:innen

ELISASARS‐CoV‐2coronavirusdiagnosticimmunoassaylateral flow immunoassaymonoclonal antibodiesnucleocapsid protein

Substanzen

Antibodies, MonoclonalCoronavirus Nucleocapsid ProteinsAntibodies, Viralnucleocapsid phosphoprotein, SARS-CoV-2PhosphoproteinsNucleocapsid Proteins

Autor:innen und Institutionen

  • United States Department of Agriculture, Agricultural Research Service, Produce Safety and Microbiology Unit, Albany, California, USA.
  • United States Department of Agriculture, Agricultural Research Service, Foodborne Toxin Detection and Prevention Unit, Albany, California, USA.

ORCID-Profile: Robert M Hnasko, Jeffery A McGarvey

Förderung

  • U.S. Department of Agriculture

Zitieren

APA

Hnasko, R. M., Lin, A. V., McGarvey, J. A., & Jackson, E. S. (2025). Immunoassay Detection of SARS ‐ CoV ‐2 Using Monoclonal Antibody Binding to Viral Nucleocapsid Protein. Microbial Biotechnology. https://doi.org/10.1111/1751-7915.70117

Vancouver

Hnasko RM, Lin AV, McGarvey JA, Jackson ES. Immunoassay Detection of SARS ‐ CoV ‐2 Using Monoclonal Antibody Binding to Viral Nucleocapsid Protein. Microbial Biotechnology. 2025. doi:10.1111/1751-7915.70117

BibTeX
@article{Hnasko2025,
  author = {Hnasko, Robert M and Lin, Alice V and McGarvey, Jeffery A and Jackson, Eric S},
  title = {Immunoassay Detection of SARS ‐ CoV ‐2 Using Monoclonal Antibody Binding to Viral Nucleocapsid Protein},
  journal = {Microbial Biotechnology},
  year = {2025},
  doi = {10.1111/1751-7915.70117}
}
Kostenlos starten →